Semaglutide Market Hits Speed Bump with ₹100 Crore Excess Stock

The explosive growth in India's obesity therapy market has faced an unexpected setback as sluggish sales lead to a massive inventory overhang. Following a period of rapid expansion, the semaglutide segment is now struggling with an estimated ₹100 crore in excess stock held across the trade channel.

The Post-Patent Surge and Subsequent Slowdown

The semaglutide market, valued at approximately ₹2,000 crore in April, experienced a massive surge following the drug's patent expiry on March 20. The entry of cheaper generic brands from major pharmaceutical players—including Sun Pharma, Dr. Reddy's, and Torrent—fueled an incredible month-on-month (m-o-m) value growth of 50% and an 88% jump in volumes in April.

However, this momentum lost significant steam in May. According to data from market research firm Pharmarack, the month-on-month value growth slowed down to just 6%, while unit growth moderated to 12%. This sudden deceleration has left the supply chain in a precarious position.

Inventory Overhang Strains the Supply Chain

The mismatch between rapid procurement in April and slower sales in May has resulted in a significant inventory glut. Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), noted that stockists and wholesalers are currently holding 50–60 days of GLP-1 (semaglutide) inventory. This is considerably higher than the industry standard of 30–45 days.

Because of this overhang, estimated to be worth nearly ₹100 crore, channel partners have effectively hit the pause button. Most stockists and wholesalers have halted fresh procurement from pharmaceutical manufacturers until the existing surplus is liquidated to prevent further losses.

Regulatory Guidelines and Market Dynamics

Industry experts suggest that the cooling of the market may not be purely a supply-demand mismatch but could be influenced by regulatory shifts. In April, government advisories and prescribing restrictions were introduced, stipulating that GLP-1 therapies should only be prescribed by qualified specialists. These tighter guidelines may have tempered the initial "gold rush" of consumer demand.

Despite the struggles in the semaglutide generic segment, the broader pharma landscape remains resilient. Eli Lilly’s Mounjaro (tirzepatide), another GLP-1 receptor agonist used for type 2 diabetes and obesity, remains the market leader. Mounjaro saw a 12% sales increase in May, reaching ₹136 crore. This growth contributed to the wider ₹2.5 lakh crore organized pharma retail market, which grew by nearly 11% during the month, largely driven by chronic therapies.

Key Takeaways

  • Inventory Crisis: The semaglutide trade channel is saddled with an estimated ₹100 crore in excess stock, with wholesalers holding up to 60 days of inventory.
  • Growth Moderation: After a massive 50% value surge in April following patent expiry, May saw value growth plummet to just 6%.
  • Regulatory Impact: Stricter prescribing guidelines requiring specialist intervention are believed to have contributed to the slowdown in sales.